Do placebo response rates from cessation trials inform on strength of addictions?

International Journal of Environmental Research and Public Health

Volumn 9, Issue 1, 2012, Pages 192-211

  Moore, Robert A ^a   Aubin, Henri Jean ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Addiction; Alcohol; Cannabis; Cocaine; Opiates; Tobacco

Indexed keywords

ACAMPROSATE; AMANTADINE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CARBAMAZEPINE; CLONIDINE; DEXAMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; MAZINDOL; METHADONE; METHYLPHENIDATE; MODAFINIL; NALTREXONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; PLACEBO; VARENICLINE;

ALCOHOL; DRUG USER; SMOKING; TOBACCO;

ABSTINENCE; ADDICTION; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COGNITIVE THERAPY; DISEASE SEVERITY; DRUG DEPENDENCE; GROUP THERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; META ANALYSIS; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PLACEBO EFFECT; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE;

CANNABIS; NICOTIANA TABACUM;

EID: 84856326287     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph9010192     Document Type: Article

References (48)

1. Lopez-Quintero, C.; Cobos, J.P.; Hasin, D.S.; Okuda, M.; Wang, S.; Grant, B.F.; Blanco, C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2010, 115, 120-130.
2. Lopez-Quintero, C.; Hasin, D.S.; de Los Cobos, J.P.; Pines, A.; Wang, S.; Grant, B.F.; Blanco, C. Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addiction 2010, 106, 657-669.
3. Miller, W.R.; Rollnick, S. Motivational Interviewing: Preparing People for Change, 2nd ed.; Guilford Press: New York, NY, USA, 2002.
4. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am. J. Prev. Med. 2008, 35, 158-176.
5. Moore, R.A.; Gavaghan, D.J.; Edwards, J.E.; Wiffen, P.; McQuay, H.J. Pooling data for number needed to treat: No problems for apples. BMC Med. Res. Methodol. 2002, 2, doi:10.1186/1471-2288-2-2.
6. Dornelas, E.A.; Sampson, R.A.; Gray, J.F.; Waters, D.; Thompson, P.D. A randomized controlled trial of smoking cessation counseling after myocardial infarction. Prev. Med. 2000, 30, 261-268.
7. Quist-Paulsen, P.; Gallefoss, F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. Br. Med. J. 2003, 327, 1254-1257.
8. Moore, R.A.; Gavaghan, D.; Tramer, M.R.; Collins, S.L.; McQuay, H.J. Size is everything-Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998, 78, 209-216.
9. Flather, M.D.; Farkouh, M.E.; Pogue, J.M.; Yusuf, S. Strengths and limitations of meta-analysis: Larger studies may be more reliable. Control Clin. Trials 1997, 18, 568-579; discussion 661-566.
10. Morris, J.A.; Gardner, M.J. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br. Med. J. 1988, 296, 1313-1316.
11. Cook, R.J.; Sackett, D.L. The number needed to treat: A clinically useful measure of treatment effect. Br. Med. J. 1995, 310, 452-454.
12. Dutra, L.; Stathopoulou, G.; Basden, S.L.; Leyro, T.M.; Powers, M.B.; Otto, M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 2008, 165, 179-187.
13. Cahill, K.; Ussher, M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD005353.pub3.
14. Gourlay, S.G.; Stead, L.F.; Benowitz, N.L. Clonidine for smoking cessation. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD000058.pub2.
15. Cahill, K.; Stead, L.F.; Lancaster, T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2011, doi:10.1002/14651858.CD006103.pub5.
16. Hughes, J.R.; Stead, L.F.; Lancaster, T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. 2010, doi:10.1002/14651858.CD000031.pub3.
17. Lancaster, T.; Stead, L.F. Individual behavioural counselling for smoking cessation. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD001292.pub2.
18. Lancaster, T.; Stead, L.F. Self-help interventions for smoking cessation. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD001118.pub2.
19. Rice, V.H.; Stead, L.F. Nursing interventions for smoking cessation. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD001118.pub2.
20. Stead, L.F.; Bergson, G.; Lancaster, T. Physician advice for smoking cessation. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD000165.pub3.
21. Stead, L.F.; Lancaster, T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD001007.pub2.
22. Stead, L.F.; Perera, R.; Bullen, C.; Mant, D.; Lancaster, T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD000146.pub3.
23. Ussher, M. Exercise interventions for smoking cessation. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD002295.pub3.
24. Wang, D.; Connock, M.; Barton, P.; Fry-Smith, A.; Aveyard, P.; Moore, D. 'Cut down to quit' with nicotine replacement therapies in smoking cessation: A systematic review of effectiveness and economic analysis. Health Technol. Assess. 2008, 12, iii-iv, ix-xi, 1-135.
25. Srisurapanont, M.; Jarusuraisin, N. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 2010, doi:10.1002/14651858.CD001867.pub3.
26. Bouza, C.; Angeles, M.; Munoz, A.; Amate, J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99, 811-828.
27. Minozzi, S.; Amato, L.; Davoli, M.; Farrell, M.; Lima Reisser, A.A.; Pani, P.P.; Silva de Lima, M.; Soares, B.; Vecchi, S. Anticonvulsants for cocaine dependence. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD006754.pub2.
28. Lima, A.R.; Lima, M.S.; Soares, B.G.; Farrell, M. Carbamazepine for cocaine dependence. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD002023.pub2.
29. Silva de Lima, M.; Farrell, M.; Lima Reisser, A.A.; Soares, B. Antidepressants for cocaine dependence. Cochrane Database Syst. Rev. 2011, 2, doi:10.1002/14651858.CD002950.pub3.
30. Soares, B.G.; Lima, M.S.; Reisser, A.A.; Farrell, M. Dopamine agonists for cocaine dependence. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD003352.
31. Amato, L.; Minozzi, S.; Pani, P.P.; Davoli, M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst. Rev. 2010, doi:10.1002/14651858.CD006306.pub2.
32. Knapp, W.P.; Soares, B.G.; Farrel, M.; Lima, M.S. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD003023.pub2.
33. Castells, X.; Casas, M.; Vidal, X.; Bosch, R.; Roncero, C.; Ramos-Quiroga, J.A.; Capella, D. Efficacy of central nervous system stimulant treatment for cocaine dependence: A systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007, 102, 1871-1887.
34. Amato, L.; Minozzi, S.; Davoli, M.; Vecchi, S.; Ferri, M.; Mayet, S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst. Rev. 2011, doi:10.1002/14651858.CD005031.pub4.
35. Farre, M.; Mas, A.; Torrens, M.; Moreno, V.; Cami, J. Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug Alcohol Depend. 2002, 65, 283-290.
36. Mattick, R.P.; Breen, C.; Kimber, J.; Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD002209.pub2.
37. Mattick, R.P.; Kimber, J.; Breen, C.; Davoli, M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD002207.pub3.
38. Gowing, L.; Ali, R.; White, J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 2009, doi:10.1002/14651858.CD002025.pub4.
39. Finniss, D.G.; Kaptchuk, T.J.; Miller, F.; Benedetti, F. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 375, 686-695.
40. Di Blasi, Z.; Harkness, E.; Ernst, E.; Georgiou, A.; Kleijnen, J. Influence of context effects on health outcomes: A systematic review. Lancet 2001, 357, 757-762.
41. Hrobjartsson, A.; Gotzsche, P.C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J. Intern. Med. 2004, 256, 91-100.
42. Miller, F.G.; Kaptchuk, T.J. The power of context: Reconceptualizing the placebo effect. J. R. Soc. Med. 2008, 101, 222-225.
43. Barden, J.; Edwards, J.E.; McQuay, H.J.; Moore, R.A. Pain and analgesic response after third molar extraction and other postsurgical pain. Pain 2004, 107, 86-90.
44. Moore, R.A.; McQuay, H.J. Bandolier's Little Book of Understanding Medical Evidence; Oxford University Press: Oxford, UK, 2006.
45. Oldman, A.D.; Smith, L.A.; McQuay, H.J.; Moore, R.A. Pharmacological treatments for acute migraine: Quantitative systematic review. Pain 2002, 97, 247-257.
46. Kalso, E.; Moore, R.A. Five easy pieces on evidence-based medicine (2). Eur. J. Pain 2000, 4, 321-324.
47. Cooney, N.L.; Litt, M.D.; Cooney, J.L.; Pilkey, D.T.; Steinberg, H.R.; Oncken, C.A. Concurrent brief versus intensive smoking intervention during alcohol dependence treatment. Psychol. Addict. Behav. 2007, 21, 570-575.
48. Woody, G.E.; Cottler, L.B.; Cacciola, J. Severity of dependence: Data from the DSM-IV field trials. Addiction 1993, 88, 1573-1579.